MedPal AI (LSE:MPAL) said its New Health pharmacy dispensed more than 2,300 prescription orders on a single day this week, worth about £0.3m. The company holds an indicative £8m term sheet from a non-bank lender, has not agreed any facility, and said no share fundraising is planned.

What was announced

MedPal AI plc (LSE:MPAL), quoted on AIM and in Frankfurt, issued a trading update on 8 October 2026. On Monday 5 October 2026, its New Health Business dispensed more than 2,300 prescription orders in one day, with a total order value of about £0.3m.

The company also set out its unaudited cash, debtors and stock position as at 6 October 2026, gave an update on Working Capital financing, and confirmed that a circular convening a general meeting will be posted by 9 October 2026.

Cash, debtors and stock

MedPal reported cash, debtors and stock totalling approximately £6.36m. Cash was about £3.39m, including roughly £0.56m due from its card payment processor. The remainder comprised a VAT receivable of about £1.40m, mainly relating to the August and September 2026 returns; NHS prescription income of about £0.36m for September, expected as an advance payment on 9 October; estimated manufacturer rebates of about £0.59m on GLP-1 medication bought in September and October; and medication stock at cost of about £0.62m.

Based on the disclosed figures, non-cash items, namely receivables, rebates and stock, account for just under £3.0m of the total, so the headline figure should not be read as cash alone.

Financing

A £5m placing was completed and settled on 24 September 2026. It was taken up mainly by existing shareholders, together with institutional and other investors. MedPal said the net proceeds are being used as set out in its 21 September announcement, principally to buy stock to meet growing order volumes.

On debt, the company has received a single indicative term sheet from a non-bank lender for an £8m facility. Discussions also continue with UK clearing banks and specialist lenders over a Facility secured against the group's receivables. The board intends to negotiate terms with each party before choosing an option. No agreement has been signed and final terms remain uncertain, so the £8m figure should be treated as indicative only. The company stated that no share fundraising has been agreed and none is planned.

Unit economics, general meeting and what to watch

MedPal explained that New Health incurs Marketing costs and offers introductory pricing to win each customer's first order, but there is no Acquisition cost from the second order onwards. Since July 2026, repeat orders have carried a positive Margin after medication costs, a margin that rises from the second order. The board expects repeat orders to contribute more to Cash Flow as more customers progress to second and later orders; this is the company's own expectation.

The general meeting is intended to restore standard share allotment authorities until the next AGM, because those granted on 30 March 2026 have been used. The authorities would allow the issue of warrants to Clear Capital Markets, announced on 6 October 2026, and provide flexibility for future fundraising or share-based acquisitions. The company stressed this does not mean any fundraising is agreed or planned.

Founder and chief executive Jason Drummond said the business continues to grow at pace, described the meeting as housekeeping to restore normal share authorities, and added that "the numbers speak for themselves." Cairn Financial Advisers is nominated adviser, with Merlin Partners and Clear Capital Markets as brokers.

Points to watch include the outcome of the Debt facility talks, the posting of the circular and the general meeting result, and whether daily order volumes are sustained.